NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study Evaluating Obicetrapib in Japanese Patients
NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced that it has initiated a Phase 2 dose-finding